Boehringer Mannheim (Germany) and Ostex continue to battle
This article was originally published in Clinica
Boehringer Mannheim (Germany) has filed a $20 million damages claim against Ostex for trying to back out of a global partnership. In August, Ostex had terminated a distribution, R&D and licence agreement with Boehringer for the osteoporosis test Osteomark. Ostex is seeking arbitration to confirm the termination (see Clinica No 669/70, p 20).
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.